NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials

Lung-MAP and ALCHEMIST, the first 'Master Protocol' trials

2014-09-25

(Press-News.org) DENVER – The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute (NCI) sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration (FDA), academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

The purpose of the NCI/FDA workshop was to collaboratively design a high priority biomarker-driven clinical trial that could expeditiously evaluate the clinical utility of a targeted-therapy in a molecularly defined lung cancer population and aid in data collection needed for regulatory approval. The workshop, whose consensus report appears in the October issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), discussed the types of biomarkers (prognostic vs predictive), the various clinical trial designs that can be employed with predictive biomarkers as well as primary endpoints for clinical trials. Also discussed were the regulatory challenges related to drug development, biomarker and biomarker assay development, trial design, and the amount of data needed for approval of both drugs and in vitro diagnostics. The attendees agreed that "in order to accelerate development of biomarker-driven trials it is critical to enhance coordination between pharmaceutical industries, FDA, academic and community-based clinical investigators, NCI, and patient organizations with the intention to enhance collaboration between these organizations, bring forward new drugs much more rapidly for approval and ultimately improving long-term outcomes for patients"

The Lung Cancer Master Protocol (Lung-MAP) clinical trial for patients with advanced lung squamous cell carcinoma was launched in June 2014. This trial is a public-private collaboration between NCI, the "Friends of Cancer" organization led by Dr. Ellen Sigal, the Southwest Oncology Group (SWOG) thoracic oncology committee led by Dr. David Gandara, Foundation Medicine, the Foundation for the National Institutes of Health, and five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune). Dr. Roy Herbst is chairing the overall steering committee and Dr. Vassiliki Papadimitrakopoulou is the overall principle investigator (PI). Patients are screened using a comprehensive genomic profiling platform that examines over 200 cancer-related genes for genomic alterations and then based on the results of this screening, patients are assigned to one of five sub-studies testing different investigational regimens best suited for their genomic profile. This innovative approach improves a patient's likelihood of receiving a drug that will work for them while allowing for new therapies in development to be added as the trial progresses.

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) launched in August 2014 and is an integrated research effort with 3 component trials for early stage non-squamous lung cancer that has been surgically resected. In the screening component trial eligible patients will have their tumor tissue tested for EGFR mutations and ALK rearrangements initially and possibly hundreds of other genomic abnormalities at disease recurrence. Those positive for EGFR mutations or ALK rearrangements will be referred to one of the treatment trials and those negative will be followed for 5 years. All patients contribute information to the national public resource for research. The Alliance for Clinical Trials in Oncology is the lead coordinating center for both the screening component (PI Dr. Pasi Jänne) and EGFR inhibitor treatment (PI Dr. Ramaswamy Govindan). Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group is the coordinating center for the ALK inhibitor treatment component (PI Dr. David Gerber).

"The concept of a "Master protocol" in lung cancer is unique for rapid identification of active drugs and a rapid pathway to drug approval based on predetermined efficacy parameters. It is a unique public-private partnership, which rapidly should lead to offering the many desperate lung cancer patients a long awaited hope", says Dr. Hirsch chair for the workshop and Chief Executive Officer of the IASLC. He adds "the Master Protocol concept is now a role model for other tumor types, such as colorectal cancer, where similar trials are planned".

INFORMATION: Co-authors Dr. Shakun M. Malik, Mark A. Socinski, William T. Sause, David H. Harpole Jr., Claudio Dansky Ullmann, and Fred R. Hirsch are members of IASLC.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,000 lung cancer specialists in 80 countries. To learn more about IASLC please visit http://www.iaslc.org

ELSE PRESS RELEASES FROM THIS DATE:

Treatment studied to help patients 'burned to the bone'

2014-09-25

An anti-inflammatory treatment, studied in the labs of regenerative medicine specialists and trauma surgeons, may prevent what's become one of the war-defining injuries for today's troops. Those burned by high-velocity explosive devices are at-risk for heterotopic ossification (HO), in which bone develops in places it shouldn't be, outside the skeleton, in joints, muscles and tendons. The painful condition can make it difficult to move and function and commonly affects patients who suffer burns, automobile accidents, orthopedic surgery and blast injuries and other combat ...

Live long and phosphor: Blue LED breakthrough for efficient electronics

2014-09-25

ANN ARBOR—In a step that could lead to longer battery life in smartphones and lower power consumption for large-screen televisions, researchers at the University of Michigan have extended the lifetime of blue organic light emitting diodes by a factor of 10. Blue OLEDs are one of a trio of colors used in OLED displays such as smartphone screens and high-end TVs. The improvement means that the efficiencies of blue OLEDs in these devices could jump from about 5 percent to 20 percent or better in the near future. OLEDs are the latest and greatest in television technology, ...

Study finds global sea levels rose up to 5 meters per century at the end of the last 5 ice age

2014-09-25

Land-ice decay at the end of the last five ice-ages caused global sea-levels to rise at rates of up to 5.5 metres per century, according to a new study. An international team of researchers developed a 500,000-year record of sea-level variability, to provide the first account of how quickly sea-level changed during the last five ice-age cycles. The results, published in the latest issue of Nature Communications, also found that more than 100 smaller events of sea-level rise took place in between the five major events. Dr Katharine Grant, from the Australian National ...

Calming down immune cells could hold key to melanoma treatment

2014-09-25

Immune cells may be responsible for drug resistance in melanoma patients, according to research published in Cancer Discovery. Cancer Research UK scientists at The University of Manchester found that chemical signals produced by a type of immune cell, called macrophages, also act as a survival signal for melanoma cells. When the researchers blocked the macrophages' ability to make this signal - called TNF alpha - melanoma tumours were much smaller and easier to treat. When melanoma patients are given chemotherapy or radiotherapy it causes inflammation, increasing ...

Interactive website helps lower-income smokers to stop smoking

2014-09-25

People with lower incomes attempting to quit smoking are 36% more likely to succeed if they use a new interactive website called 'StopAdvisor' than if they use a static information website, finds a randomised controlled trial led by UCL researchers. The trial was funded by the National Prevention Research Initiative, a consortium of 16 UK health research funders. A total of 4,613 smokers took part in the study, of whom 2,142 were classified into a 'lower income' group who had never worked, were long term unemployed or from routine or manual occupations (lower socioeconomic ...

Skirt size increase linked to 33 percent greater postmenopausal breast cancer risk

2014-09-25

Overall weight gain during adulthood is known to be a risk factor for breast cancer, but a thickening waist seems to be particularly harmful, indicating the importance of staving off a midriff bulge, the research shows. The researchers base their findings on almost 93,000 women taking part in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) in England. The women were all aged over 50, had gone through the menopause, and had no known breast cancer when they entered the study between 2005 and 2010. At enrolment they provided detailed information on height ...

The Lancet Diabetes & Endocrinology: Working long hours linked to increased risk of type 2 diabetes

2014-09-25

People working for more than 55 hours per week doing manual work or other low socioeconomic status jobs have a 30% greater risk of developing type 2 diabetes, according to the largest study in this field so far, published in The Lancet Diabetes & Endocrinology. Mika Kivimäki, Professor of Epidemiology at University College London, UK, and colleagues conducted a systematic review and meta-analysis of published studies and unpublished individual-level data examining the effects of long working hours on type 2 diabetes up to 30 April 2014. Analysis of data from 4 published ...

Identification of genetic risk factors for stroke

2014-09-25

Stroke is one of the leading causes of death worldwide. While many lines of evidence suggest that stroke risk is heritable, only a small number of genes associated with stroke have been identified. A new study in the Journal of Clinical Investigation identifies two genes that underlie cerebral small-vessel disease (CSVD), a risk factor for stroke. Ordan Lehmann and colleagues at the University of Alberta analyzed genome-wide association data from individuals that received brain MRI scans as part of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) ...

Wound healing response promotes breast cancer metastasis in postpartum mice

2014-09-25

Within the first 5 years after the birth of a child, women are at an increased risk of developing metastatic breast cancer. Women diagnosed with postpartum breast cancer have a decreased disease free survival time compared to women that have never given birth. The aggressive tendency of postpartum breast cancer suggests that the post-birth breast environment promotes tumor metastasis. A new study in the Journal of Clinical Investigation, suggests that dying tumor cells in postpartum breast tissue promote metastatic disease. Rachel Cook and colleagues at Vanderbilt University ...

Memory slips may signal increased risk of dementia years later

2014-09-24

MINNEAPOLIS – New research suggests that people without dementia who begin reporting memory issues may be more likely to develop dementia later, even if they have no clinical signs of the disease. The study is published in the September 24, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. "What's notable about our study is the time it took for this transition to dementia or clinical impairment to occur—about 12 years for dementia and nine years for clinical impairment—after the memory complaints began," said study author Richard ...

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

The American Pediatric Society names Dr. Beth Tarini as the recipient of the 2025 Norman J. Siegel New Member Outstanding Science Award

New Clinical Study Confirms the Anti-Obesity Effects of Kimchi

[Press-News.org] NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials
Lung-MAP and ALCHEMIST, the first 'Master Protocol' trials

NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: